a year ago

Senisca Secures £3.7 Million Funding to Advance Senotherapeutic Programs

  • Senisca, a UK-based biotechnology company developing RNA-based senotherapeutics to treat age-related disease, raised an additional £3.7 million in funding

  • This round brought the total amount to £7.1 million, with participation from Emerging Longevity Ventures, QantX, the R42 Group, Trend Investment Group, and Apex Ventures, and investment from new funds including Lifespan Vision Ventures

  • The funds will be used to support continued evolution and the preclinical development of its senotherapeutic programs, targeting the causes of age-related disease via RNA splicing regulation, resulting in cellular reprogramming and disease modification by attenuating senescence

  • Senisca is a spinout from the University of Exeter that has developed proprietary technology that harnesses RNA biology to reprogram aged ‘senescent’ cells.

      • ProblemHealthcare

      "Age-related diseases are a growing global health challenge. Currently, there are limited effective treatments available to address the underlying causes of these diseases."

      Solution

      "Senisca's technology uses RNA-based senotherapeutics to reprogram aged cells and slow down the aging process. Their approach targets the root cause of age-related diseases by regulating RNA splicing, a process that controls gene expression, and reversing cellular senescence."

      Covered on